Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

开始日期2022-11-21

申办/合作机构

Stanford University

NCT05226533 / Terminated临床2期

A Phase 2, Double Blind, Randomized, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of DWRX2003 in Combination With Remdesivir Following Intramuscular Administration in Moderate-Severe COVID-19 Patients

Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.

开始日期2022-03-31

申办/合作机构

Daewoong Pharmaceutical Co., Ltd.

NCT04542434 / Withdrawn临床2期

A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19

This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms

开始日期2022-01-20

申办/合作机构

First Wave Biopharma, Inc.

100 项与氯硝柳胺相关的临床结果

登录后查看更多信息

100 项与氯硝柳胺相关的转化医学

登录后查看更多信息

100 项与氯硝柳胺相关的专利（医药）

登录后查看更多信息

1,129

项与氯硝柳胺相关的文献（医药）

2106-07-05·Oncotarget

Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling

Article

作者: Gao, Yun ; Zhang, Junxiang ; Wang, Jing ; Yin, Lina ; Ding, Defang ; Chen, Honghong ; Zhang, Xuxia ; Zhang, Yaping

Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC. We herein reported that ionizing radiation (IR) induced Wnt3a, LRP6 and β-catenin expression and consequently activated Wnt/β-catenin signaling in TNBC MDA-MB-231, MDA-MB-468 and Hs578T cells. Moreover, depletion of β-catenin by shRNA sensitized TNBC cells to IR, whereas treatment of Wnt3a protein or overexpression of β-catenin resulted in radioresistance of TNBC cells. Niclosamide, a potent inhibitor of Wnt/β-catenin signaling, not only inhibited constitutive Wnt/β-catenin signaling, but also blocked IR-induced Wnt/β-catenin signaling in TNBC cells. In addition, niclosamide sensitized TNBC cells to IR, prevented Wnt3a-induced radioresistance, and overcame β-catenin-induced radioresistance in TNBC cells. Importantly, animals treated with the combination of niclosamide and γ-ray local tumor irradiation had significant inhibition of MDA-MB-231 tumor growth compared with treated with local tumor irradiation alone. These findings indicate that Wnt/β-catenin signaling pathway plays an important role in the development of radioresistance of TNBC cells, and that niclosamide had significant radiosensitizing effects by inhibiting Wnt/β-catenin signaling in TNBC cells. Our study also provides rationale for further preclinical and clinical evaluation of niclosamide in TNBC management.

2024-05-01·International Immunopharmacology

STAT3 promotes cytoplasmic-nuclear translocation of RNA-binding protein HuR to inhibit IL-1β-induced IL-8 production

Article

作者: Song, Yinghui ; Jiang, Manli ; Liu, Xueting ; Xiang, Yangen ; Wang, Yufei ; Zhao, Wang ; Hu, Jinyue ; Xiang, Wei ; Long, Jiangwen

Signal transducer and activator of transcription 3 (STAT3) functions to regulate inflammation and immune response, but its mechanism is not fully understood. We report here that STAT3 inhibitors Stattic and Niclosamide up-regulated IL-1β-induced IL-8 production in C33A, CaSki, and Siha cervical cancer cells. As expected, IL-1β-induced IL-8 production was also up-regulated through the molecular inhibition of STAT3 by use of CRISPR/Cas9 technology. Unexpectedly, IL-1β induced IL-8 production via activating ERK and P38 signal pathways, but neither STAT3 inhibitors nor STAT3 knockout affected IL-1β-induced signal transduction, suggesting that STAT3 decreases IL-8 production not via inhibition of signal transduction. To our surprise, STAT3 inhibition increased the stabilization, and decreased the degradation of IL-8 mRNA, suggesting a post-transcriptional regulation of IL-1β-induced IL-8. Moreover, Dihydrotanshinone I, an inhibitor of RNA-binding protein HuR, down-regulated IL-1β-induced IL-8 dose-dependently. HuR inhibition by CRISPR/Cas9 also decreased IL-8 production induced by IL-1β. Mechanistically, co-immunoprecipitation results showed that STAT3 did not react with HuR directly, but STAT3 inhibition increased the protein levels of HuR in cytoplasm. And IL-6 activation of STAT3 induced HuR cytoplasmic-nuclear transport. Taken together, these results suggest that STAT3 contributes to HuR nuclear localization and inhibits Il-1β-induced IL-8 production through this non-transcriptional mechanism.

2024-05-01·Tuberculosis

Computational drug repositioning identifies niclosamide and tribromsalan as inhibitors of Mycobacterium tuberculosis and Mycobacterium abscessus

Article

作者: Ding, Ying ; Lane, Thomas R ; Puhl, Ana C ; Wild, David J ; Yang, Jeremy J ; Passi, Anurag ; Goff, Aaron ; Foote, Brian ; London, Shelley ; Waddell, Simon J ; Duerksen, Joel L ; Ekins, Sean ; Braunstein, Miriam ; Annis, Ayano ; Kerber, Randy

Tuberculosis (TB) is still a major global health challenge, killing over 1.5 million people each year, and hence, there is a need to identify and develop novel treatments for Mycobacterium tuberculosis (M. tuberculosis). The prevalence of infections caused by nontuberculous mycobacteria (NTM) is also increasing and has overtaken TB cases in the United States and much of the developed world. Mycobacterium abscessus (M. abscessus) is one of the most frequently encountered NTM and is difficult to treat. We describe the use of drug-disease association using a semantic knowledge graph approach combined with machine learning models that has enabled the identification of several molecules for testing anti-mycobacterial activity. We established that niclosamide (M. tuberculosis IC₉₀ 2.95 μM; M. abscessus IC₉₀ 59.1 μM) and tribromsalan (M. tuberculosis IC₉₀ 76.92 μM; M. abscessus IC₉₀ 147.4 μM) inhibit M. tuberculosis and M. abscessus in vitro. To investigate the mode of action, we determined the transcriptional response of M. tuberculosis and M. abscessus to both compounds in axenic log phase, demonstrating a broad effect on gene expression that differed from known M. tuberculosis inhibitors. Both compounds elicited transcriptional responses indicative of respiratory pathway stress and the dysregulation of fatty acid metabolism.

131

项与氯硝柳胺相关的新闻（医药）

2024-04-29

·GlobeNewswire-Health Care

TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting

Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene Expression Biomarker Data Demonstrate that Treatment with TFF TAC Leads to Normalization of Expression of Rejection-Related Genes FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that data from the Company’s ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection is available on the Company’s website. These data were recently presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2 study, via an oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 44th Annual Meeting during a late breaking clinical science abstract session on April 13, 2024. The data became available following the Company’s 8-K filing. “Following the presentation of these updated data from our ongoing Phase 2 study of TFF TAC at this year’s ISHLT meeting, we have received highly positive feedback from the transplant medicine community, indicating heightened awareness of this innovative program and a growing enthusiasm for its potential to improve upon the current standard of care,” said Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. “Looking ahead, we are focused on advancing this highly innovative program into potentially registrational testing, and we look forward to sharing additional data from the TFF TAC Phase 2 trial later this year.” “These unprecedented results from our Phase 2 study provide evidence that TFF TAC has the potential to optimize lung immune suppression at decreased systemic exposures. TFF TAC can prevent rejection of the transplanted lung when delivered at only one-sixth of the oral tacrolimus dose and at two-thirds of the oral tacrolimus systemic trough exposures, levels predicted to decrease systemic toxicities,” said Dr. Zamaneh Mikhak, Chief Medical Officer of TFF Pharmaceuticals. “In addition, our gene expression data demonstrate that TFF TAC normalizes the expression of genes associated with lung transplant rejection in patients whose systemic exposures are decreased, providing evidence at a molecular level that treatment with TFF TAC can increase lung immune suppression at reduced systemic exposures. These data collectively point to the potential opportunity to improve efficacy as well as safety after lung transplantation with TFF TAC.” ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGYTFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by TFF can deliver as much as 75% of the dose to the deep lung. TFF does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. ABOUT TFF PHARMACEUTICALSTFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by over 170 patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com. SAFE HARBOR This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the advancement of TFF TAC into potentially registration-enabling studies; the expectation that the initial data readouts for TFF TAC will be consistent with the further data from the ongoing Phase 2 clinical trial; and the benefits of the Company’s TFF platform. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 2 clinical trial for TFF TAC will not be favorably consistent with the initial data initial data readouts, (ii) the risk that the Company may not be able to advance to registration-enabling studies for its TFF TAC candidate, (iii) success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iv) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (v) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the Phase 2 clinical trial, or advance to the initiation of registration-enabling studies, for TFF TAC as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 28, 2024. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. Investor Relations Contact:Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577cdavis@lifesciadvisors.com

临床2期

2024-04-25

·PRNewswire

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

"Aiming to offer a Dengue antiviral treatment course in $100 price range" Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in Brazil, which has the highest number of dengue cases and deaths in the world. Hyundai Bioscience outlined two main reasons for choosing Brazil as its Dengue clinical trial regions: Firstly, Brazil has been the most affected country by the Dengue virus. According to the Brazilian health authorities, as of April 10th this year, there has been 3,062,181 reported cases of Dengue infections with 1,256 deaths. Brazilian health authorities expect the number of infections this year to more than double last year's 1.6 million cases. 71 cities in Southern Brazil, including São Paulo and Rio de Janeiro, have declared a public health emergency over Dengue. Secondly, Brazil offers a fast-track process for drugs targeting diseases with no available treatments. Although the number of Dengue cases and deaths is rapidly increasing not only in Brazil but globally, there is no antiviral treatment available. Niclosamide, the active pharmaceutical ingredient of Hyundai Bioscience's Dengue antiviral, has been known to have antiviral efficacy against all serotypes of Dengue viruses through previous in vitro studies, and its safety has also been confirmed through Hyundai Bioscience's preclinical and clinical studies for COVID-19. This may enable to skip preclinical study and to proceed promptly to clinical study through the fast-track approval process. Dengue treatment has not been developed for over 50 years since the Dengue virus was discovered. Development of Dengue treatments is challenging because it must be effective against all four serotypes of the Dengue virus as well as against their mutants. Hyundai Bioscience has successfully repurposed Niclosamide for Dengue antiviral through its patented drug delivery system technology using inorganics and polymers that are harmless to the human body. With its proprietary technology, Hyundai Bioscience has overcome the challenges of low bioavailability and short half-life of Niclosamide which has pan-serotype antiviral efficacy against Dengue according to the past in vitro studies. Hyundai Bioscience completed the development of a Niclosamide-based formulation for Dengue treatment, which enables drug concentration at 50% viral inhibition level (IC 50) or higher to inhibit the proliferation of four serotypes of the Dengue virus as well as Zika, Chikungunya, and Yellow fever viruses. Hyundai Bioscience stated that Dengue can be treated effectively if the antiviral is administered early stage of the infection before the viral load rapidly increases. Early treatment may be possible if the drug can treat not only Dengue but also other mosquito-borne viral infections such as Zika and Chikungunya that show similar symptoms to Dengue. The new Niclosamide-based Dengue antiviral formulated by Hyundai Bioscience has a broad-spectrum antiviral efficacy that can treat not only Dengue infection but other mosquito-borne viral infections; hence, early and effective Dengue treatment may be possible with effective early administration before a rapid viral load increase. Hyundai Bioscience plans to conduct a basket-type clinical trial in Brazil (confirmatory clinical study for Dengue and exploratory clinical study for other mosquito-borne viral infections). This involves administering the antiviral early to patients infected by any of the four serotypes of the Dengue virus as well as those infected by other mosquito-borne viruses such as Zika and Chikungunya, and then evaluating the drug's efficacy in the Dengue-confirmed patient population. According to the World Health Organization (WHO)'s announcement on March 28, 2024, the number of Dengue cases in the Americas reached 3,578,414 in 2024, with 1,039 deaths. This figure is 3 times the number of Dengue cases reported at the same time in 2023. The global market for Dengue treatments is expected to grow from $880 million in 2023 to $5.4 billion by 2033. "The success of Dengue clinical study on our Niclosamide-based antiviral could lead to its emergency use authorization not only in Brazil but also in other countries. We plan to set the supply price in the $100 range", said Dr. Kim Kyung-Il, CEO of Hyundai Bioscience USA. About Hyundai Bioscience Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). SOURCE Hyundai Bioscience

临床研究快速通道

2024-04-25

·PRNewswire

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost all cancer types and cause intractable cancers such cases found in ovarian cancer, uterine cancer, esophageal cancer, etc. The p53 gene acts as the "guardian of the genome," detecting cellular DNA damage and inducing cell death. When mutated, the p53 gene loses its function, leading to resistance to existing anticancer drugs and rapid metastasis of cancer cells. While R&D attempts have been made to develop anticancer agents that target p53 mutated cancer cells, those attempts have failed to selectively kill p53 mutated cancer cells without damaging normal cells. Previous researches have shown evidences that niclosamide is a promising metabolic anticancer agent. Niclosamide can induce cancer cell death by regulating cancer cell metabolic pathways and can resolve drug resistance and cancer cell metastasis while minimizing side effects. It also enhances anticancer effects when used in combination therapy with existing anticancer drug. Niclosamide, however, has not been developed as an anticancer drug for over 60 years due to its low bioavailability and short half life. With its patented drug delivery system technology, Hyundai Bioscience succeeded in developing niclosamide as an oral anticancer agent by reaching the necessary drug concentration level (IC50) to inhibit the proliferation of most cancer cells at non-toxic (NOAEL) dose. Recently, in a triple-negative breast cancer in vivo studies, Hyundai Bioscience demonstrated that the combination therapy group with oral niclosamide-based anticancer agent and docetaxel, the widely-used chemotherapeutic drug, showed 67% higher anticancer effects compared to the docetaxel-alone treatment group. Long-term (13 weeks) animal toxicity tests confirmed that the blood concentration when administering the No-observed-adverse-effect level (NOAEL) of Niclosamide was 7,888 ng/mL. Considering that the IC50 for most types of cancer cell is 65~654 ng/mL, niclosamide is expected to inhibit the proliferation of most cancer cell types even when administered at less than one-tenth of the NOAEL. Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline." Jong-Eon Lim, CEO of ADM Korea, mentioned, "We plan to submit IND for a clinical trial that is designed to compare the combination therapy group with niclosamide-based anticancer drug and existing anticancer drugs treatment against the single-agent therapy group," and added, "With this clinical trial, we will advance into a biotech specialized in oral metabolic anticancer agent." About Hyundai Bioscience Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). SOURCE Hyundai Bioscience

临床研究

100 项与氯硝柳胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00436	氯硝柳胺	P02DA01	DB06803

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃肠道感染	临床2期	美国	First Wave Biopharma, Inc.	2021-04-30
胃肠道感染	临床2期	乌克兰	First Wave Biopharma, Inc.	2021-04-30
胃肠道感染	临床2期	印度	First Wave Biopharma, Inc.	2021-04-30
新型冠状病毒感染	临床2期	美国	NeuroBo Pharmaceuticals, Inc.	2020-10-07
直肠结肠炎	临床2期	意大利	First Wave Biopharma, Inc.	2018-05-15
克罗恩病	临床1期	-	First Wave Bio, Inc.	-
新型冠状病毒感染	临床前	美国	NeuroBo Pharmaceuticals, Inc.	2020-10-07
糖尿病肾病	临床前	埃及	Tanta University	2020-02-01
溃疡性直肠炎	临床前	意大利	First Wave Bio, Inc.	2018-05-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04399356 (Pubmed) 人工标引	临床2期	新型冠状病毒感染	73	Niclosamide	鑰顧顧遞糧鹹鹹遞繭衊(遞壓衊艱餘膚顧顧蓋鹹) = 網襯餘醖遞淵觸窪壓選網鑰願繭衊築積製築鹹 (簾製夢壓鏇淵選糧簾憲, 50.74 ~ 81.81) 更多	不佳	2022-02-01
				Placebo	鑰顧顧遞糧鹹鹹遞繭衊(遞壓衊艱餘膚顧顧蓋鹹) = 鬱積簾製艱簾鹹簾積艱網鑰願繭衊築積製築鹹 (簾製夢壓鏇淵選糧簾憲, 40.27 ~ 72.73) 更多
NCT02807805 (ASCO2018)	临床2期	去势抵抗性前列腺癌	6	Niclosamide/PDMX1001 + Abiraterone + Prednisone	(餘鹽衊膚衊鏇觸網網鹽) = two with partial PSA response (≥50% decrease) 壓糧鑰簾觸獵簾鏇蓋衊 (遞夢鹹鹽遞鏇積膚鬱遞 ) 更多	积极	2018-06-01
NCT04576312 (Pubmed) 人工标引	临床1期	新型冠状病毒感染	44	UNI91104	積艱齋蓋鹽齋淵積廠餘(蓋窪鑰淵簾構醖窪廠膚) = 壓壓積膚範鏇膚選鑰鹽鑰觸憲廠襯鬱醖艱齋積 (願窪積鑰繭製築鑰齋獵 )	积极	2021-05-01
				Placebo	積艱齋蓋鹽齋淵積廠餘(蓋窪鑰淵簾構醖窪廠膚) = 艱鬱壓鏇鏇壓蓋淵蓋觸鑰觸憲廠襯鬱醖艱齋積 (願窪積鑰繭製築鑰齋獵 )
NCT04317430 (Literature) 人工标引	临床3期	糖尿病肾病	60	niclosamide+ramipril	(憲顧廠觸顧蓋蓋壓繭獵) = 餘製憲簾糧蓋網壓糧鏇鹹襯窪繭遞簾鹽淵繭築 (窪顧範糧憲夢醖淵憲積, -30to-18.3) 更多	积极	2023-02-16
				ramipril	(憲顧廠觸顧蓋蓋壓繭獵) = 醖齋範淵鏇遞構製醖鹽鹹襯窪繭遞簾鹽淵繭築 (窪顧範糧憲夢醖淵憲積, 4to18.2) 更多
NCT04399356 (CTgov)	临床2期	新型冠状病毒感染	73	Niclosamide (Niclosamide- Experimental Group)	積獵觸願鹹網鬱顧齋顧(繭艱積鹽鏇膚醖願願蓋) = 鹹遞襯獵夢獵膚窪蓋構襯鹹壓醖範鏇獵鹽選願 (簾壓蓋夢鹽顧廠選醖衊, 醖窪蓋觸鹽壓簾鑰襯憲 ~ 齋獵襯積艱繭構觸蓋簾) 更多	-	2022-04-12
				placebo (Control Group)	積獵觸願鹹網鬱顧齋顧(繭艱積鹽鏇膚醖願願蓋) = 窪醖夢鹹積範醖壓繭鬱襯鹹壓醖範鏇獵鹽選願 (簾壓蓋夢鹽顧廠選醖衊, 觸窪選襯鏇窪製蓋願觸 ~ 範廠衊網製製衊糧夢鹽) 更多